Adjuvant tamoxifen (TEAM): a randomised trial in postmenopausal women with hormone-sensitive early breast cancer


Summary

Background
Aromatase inhibitors improved disease-free survival after adjuvant tamoxifen or after 2–3 years of tamoxifen. We therefore compared the effect of exemestane in postmenopausal women with hormone-sensitive breast cancer.

Methods
The Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial randomised 9797 women to tamoxifen or exemestane. The primary end point was disease-free survival. The trial was registered in ClinicalTrials.gov (NCT00279448, NCT00032136 and NCT00036270; NTR 267; Ethics Commission Trial 27/2001; and UMIN, C000000057).

Findings
9797 women were assigned to sequential treatment (n = 4875) or exemestane alone (n = 4902), and 4868 and 4898 were assessable for disease-free survival and progression-free survival, respectively.
The TEAM Trial pathology study identifies potential prognostic and predictive biomarker models for patients treated with endocrine therapy.

1Endocrine Cancer Group, Edinburgh University, Scotland; 2Cancer Research UK Clinical Trials Unit, The University of Birmingham, Birmingham, United Kingdom; 3University Hospital Freiburg, Freiburg, Germany; 4Erasmus MC Daniel Den Hoed, Rotterdam, the Netherlands; 5Helios Medical Center Aue, Germany; 6Athens University Medical School, Greece; 7Department of Pathology, WI, Glasgow, UK 8U. Z. Gasthuisberg, Leuven, Belgium; 8Jichi Medical University, Shimotsuke, Japan; 9Leiden University Medical Center, Leiden, The Netherlands;
Συνεχίζεται η συλλογή στοιχείων
- F/up: 1. alive or dead / cause of
  2. recurrence / site of ,
  3. f/up medicine >5yrs